8-K: Crinetics Pharmaceuticals Enters Consulting Agreement with Former CFO Marc Wilson
8-K Filing
Crinetics Pharmaceuticals has engaged its former CFO, Marc Wilson, as an independent consultant to provide accounting and finance services for a one-year period.
Summary
- Crinetics Pharmaceuticals entered into an Independent Consultant Agreement with Marc Wilson, the former CFO, effective April 1, 2025.
- Wilson will provide services related to accounting and finance for $300 per hour.
- The agreement is for a one-year period, with a possible six-month renewal.
- Certain of Wilson's outstanding equity awards will continue to vest during the consulting period.
- Wilson has agreed to a general release of all claims against the company related to his departure.
- The company will extend certain indemnification rights to Wilson during the consulting period.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. Retaining the former CFO as a consultant provides continuity and expertise, but also incurs additional costs.
Positives
- Crinetics retains the expertise of its former CFO for accounting and finance matters.
- The agreement includes a release of claims, reducing potential legal risks.
- Continued vesting of equity awards may incentivize Wilson to provide high-quality consulting services.
- The company extends indemnification rights to Wilson during the consulting period.
Negatives
- The company will incur consulting fees of $300 per hour.
- Continued vesting of equity awards represents additional compensation to a former executive.
- The agreement extends indemnification rights to Wilson during the consulting period.
Risks
- Potential conflicts of interest if Wilson provides services to other companies.
- Dependence on a single consultant for critical accounting and finance matters.
- Risk of disputes arising from the consulting agreement.
Future Outlook
The consulting agreement may be renewed for an additional six-month period if mutually agreed upon by both parties.
Industry Context
It is common for companies to engage former executives as consultants to leverage their expertise and ensure a smooth transition.
Comparison to Industry Standards
- Consulting fees of $300 per hour are within the typical range for experienced financial consultants.
- Extending equity vesting to consultants is a common practice to incentivize continued service and align interests.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Financial Officer | Marc Wilson | Tobin Toby Schilke | February 28, 2025 | Transition of duties |
Related Party Transactions
- The Independent Consultant Agreement with former CFO Marc Wilson is a related-party transaction.
Stakeholder Impact
- Shareholders: The agreement ensures continuity in financial expertise but also represents an additional expense.
- Employees: The transition may impact the workload and responsibilities of other finance department employees.
- Management: The agreement provides access to Wilson's expertise and facilitates a smooth transition.
Next Steps
- Marc Wilson will provide accounting and finance consulting services to Crinetics Pharmaceuticals.
- The consulting agreement may be renewed for an additional six months.
- Wilson's equity awards will continue to vest during the consulting period.
Key Dates
| Date | Description |
|---|---|
| May 22, 2018 | Date of the Amended and Restated Employment Agreement between Crinetics Pharmaceuticals and Marc Wilson. |
| August 8, 2024 | Date of a previous Form 8-K filing regarding Marc Wilson's departure. |
| February 24, 2025 | Date of a previous Form 8-K filing regarding Marc Wilson's departure. |
| February 28, 2025 | Effective date of Marc Wilson ceasing to serve as Chief Financial Officer. |
| April 1, 2025 | Effective date of Marc Wilson's resignation as an employee and commencement of the Independent Consultant Agreement. |
| April 1, 2026 | Scheduled end date of the initial Consulting Period, with a possible six-month renewal. |
Keywords
Independent Consultant Agreement, Marc Wilson, Chief Financial Officer, Crinetics Pharmaceuticals, Consulting, Equity Awards, Indemnification, Accounting, Finance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.